GlassScriptPhysician profile
Yawen Wang
NPI 1275821720
$17,148.51
in general payments reported to CMS, 2019-2025
72 companies · $2,302 in 2025
The $2,302 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $101 · 2020: $1,409 · 2021: $3,118 · 2022: $4,026 · 2023: $3,550 · 2024: $2,644 · 2025: $2,302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,495.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,495.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,896.06 | 2021-2025 | Botox, Qulipta, Ubrelvy |
| Ucb, INC. | $1,318.38 | 2020-2025 | Briviact, Nayzilam, Fintepla |
| Biogen, INC. | $1,241.15 | 2020-2023 | Vumerity, Tysabri, Tysabri |
| Neurocrine Biosciences, INC. | $1,024.58 | 2019-2025 | Ingrezza, Ongentys |
| Livanova USA, INC. | $933.11 | 2020-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Emd Serono, INC. | $827.74 | 2021-2024 | Mavenclad |
| Neurelis, INC. | $701.65 | 2020-2024 | Valtoco |
| Sk Life Science, INC. | $584.50 | 2020-2025 | Xcopri |
| Lilly USA, LLC | $504.63 | 2021-2025 | Emgality, Reyvow, Kisunla |
| Novartis Pharmaceuticals Corporation | $473.46 | 2020-2025 | |
| Merz Pharmaceuticals, LLC | $454.24 | 2021-2025 | Xeomin, Inbrija |
| Pfizer INC. | $426.79 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $390.95 | 2020-2024 | Ultomiris, Soliris |
| Abbott Laboratories | $373.61 | 2021-2023 | Infinity |
| Teva Pharmaceuticals USA, INC. | $369.72 | 2020-2024 | Austedo Xr |
Show all 72 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yawen Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.